An observational study in Relapsing Multiple Sclerosis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-29.
Sponsored by Merck KGaA, Darmstadt, Germany · Observational
The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 545 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Merck KGaA, Darmstadt, Germany is the lead sponsor of 269 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients in the UK newly diagnosed with RMS (and naive to previous DMT) and receiving a DMT that can be self-administered
Exclusion Criteria:
Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
Drug: Rebif
Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
Other: Other: Disease modifying therapies (DMT)
The subjects will receive Rebif as per the current practices or as directed by the physician.
The subjects will receive other DMTs as per the current practices or as directed by the physician.
Treatment Satisfaction
The survey sample size has been calculated based on the TSQM-9 questionnaire in order to compare scores between both patient cohorts.
Time frame: 96 weeks
Work Productivity
Work Productivity and Activity Impairment (WPAI) Questionnaire
Time frame: 96 weeks
Health Related Quality of Life
Multiple Sclerosis Impact Scale (MSIS-29) v2.0 Questionnaire
Time frame: 96 weeks
Health Related Quality of Life EuroQoL (EQ-5D)-5L Questionnaire
Time frame: 96 weeks
Device satisfaction
Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ) is an MS-specific treatment satisfaction questionnaire that evaluates injection system satisfaction and side effects.
Time frame: 96 weeks
Evaluation of support services
Patient evaluation of Manufacturer, Homecare and NHS support services
Time frame: 96 weeks
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck KGaA, Darmstadt, Germany